Three meta-analyses define a set of commonly overexpressed genes from microarray datasets on astrocytomas

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Genomics

Background:

• Astrocytoma, a common central nervous system tumor, necessitates deeper molecular understanding.
• Microarray technology and meta-analysis are crucial for robust cancer research.
• Identifying novel biomarkers is vital for astrocytoma diagnosis and treatment.

Purpose of the Study:

• To identify common differentially expressed genes (DEGs) in astrocytomas compared to normal brain tissue.
• To validate the mRNA and protein expression of key cell cycle genes in astrocytoma tissues.
• To assess the potential diagnostic and therapeutic value of identified genes in astrocytoma.

Main Methods:

• Integration of four microarray datasets (GSE16011, GSE4290, GSE2223, GSE19728) using three meta-analyses.
• Identification of common differentially expressed genes (DEGs).
• Validation of PCNA, CDC2, CDK2, and CCNB2 expression using Real-Time Polymerase Chain Reaction (RT-PCR) and immunohistochemistry.

Main Results:

• Four common DEGs (PCNA, CDC2, CDK2, CCNB2) involved in the cell cycle pathway were identified.
• PCNA expression served as a validation reference, confirming the methodology's accuracy.
• The study provides the first validation of CDC2, CDK2, and CCNB2 mRNA and protein levels in human astrocytoma tissues.

Conclusions:

• The identified genes (PCNA, CDC2, CDK2, CCNB2) play a significant role in astrocytoma development.
• These genes show potential as valuable biomarkers for astrocytoma diagnosis.
• Further research into these genes may lead to novel therapeutic strategies for astrocytoma.